1 / 23

Revolade 75mg tablets | Eltrombopag | MHP

Eltrombopag is sold under the brand name Revolade and it is a man-made form of a protein that increases production of platelets in your body @ MHP

MelanieGraces
Download Presentation

Revolade 75mg tablets | Eltrombopag | MHP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ELTROMBOPAG 75MG|MHP REVOLADE 75 MG

  2. DESCRIPTION • Eltrombopag is sold under the brand name Revolade and it is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body. Revolade 75mg can reduces the risk of bleeding by increasing platelets in your blood.Revolade75mgtablet which is used asprescription drug under the guidance of the medical practioners

  3. INDICATION

  4. INDICATION • Revolade 75mgis an anticancer medication which is;Indicated for the treatment of patients having Severe aplastic Anemia• First line treatment of severe aplastic Anemia• Treatment of refractory severe aplastic AnemiaIndicated for the treatment to stimulate the growth and development of platelets in the bone marrowPrimarily indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection

  5. INDICATION

  6. MECHANISM OF ACTION

  7. MECHANISM OF ACTION • Eltrombopag consist of class of drugs known as thrombopoietin (TPO) receptor agonists. A class of drugs is a group of medications which work in a same way.Eltrombopag mechanism by raising cells in your bone marrow and causes these cells to make more platelets. This effect reduces your risk of bleeding.

  8. PROPERTIES

  9. PROPERTIES • Ingredients :Eltrombopag • Strength :75mg • Package : 7 tablets in a strip

  10. ADD ME • Absorption:High plasma concentration is 2-6 hours • Distribution:Maximum human plasma protein bounding is >99% and in blood plasma level is 50% to 79% • Metabolism: generally metabolised via cleavage, oxidation and conjugation with glucuronic acid.

  11. ADD ME • Elimination:Revolade 75mg eliminated mainly via feces 59%, along with 31% via renallyexcreted • Revolade75mg Half-life for healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

  12. DOSAGE MANAGEMENT • The usual dose for Chronic Hepatitis C-associated Thrombocytopenia is 25 mg PO qDay. Dose is managed in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day.

  13. Severe Aplastic Anemia • First-line therapy :When combination with standard immunosuppressive treatment, for patients with serious aplastic Anemia (SAA) The usual dose for severe Aplastic Anemia: 150 mg PO qDay for 6 months Avoid taking of more than starting dose; total duration is 6 months 

  14. Severe Aplastic Anemia • Refractory SAA :In this condition the drug given who fail to respond enough to at least 1 before immunosuppressive therapy The usual dose for Refractory SAA: 50 mg PO qDay

  15. Severe Aplastic Anemia • The recommended dose for Chronic Immune Thrombocytopenia is 50 mg PO qDay Adjust dose to manage and control platelet count (Plt) >50 x 10^9/L to reduce the risk of bleeding; not to exceed 75 mg/day

  16. PRECAUTIONS • The drug Revolade 75mg may have high risk of severe and probably life-threatening hepatotoxicity; monitor liver function before and during treatment • While receiving the drug, if patient with hepatic impairment (Child-Pugh Class A, B, C) initiates therapy for first- line treatment of severe aplastic Anemia, reduce initial dose

  17. PRECAUTIONS • When treatment, If the patients have cataracts, do not use the drug due to the Revolade 75mg effects cataracts and make the condition worse. • Avoid the Revolade 75mg while the patients have myelodysplastic syndrome (MDS), will increases the risk of death. • While on treatment with drug Revolade then Portal vein thrombosis reported in patients with chronic liver disease.

  18. SIDE EFFECTS • Common side effects of Revolade 75mg :• Headache• Cough• Loss of appetite• Flu• Reduced red blood cells• Diarrhoea• Nausea• Fever• Weakness

  19. SIDE EFFETCS • Serious side effects of Revolade 75mg :• Swelling of legs• Abdomen swelling• Confusion• Chest pain• Dyspnea• Cloudy vision• Urine in dark colour• Yellowing of your skin• Sensitivity to light• Seeing circles around lights

  20. DRUG INTERACTION • PREGNANCY Pregnancy category is C Safety of drug during pregnancy is not established • LACTATION During breast feeding, avoid using of drug Revolade 75mg • STORAGE Store at room temperature 20°C and 25°C.

  21. CONTACT US • PHONE NO +91-9940472902 • EMAIL millionhealthpharmaceuticals@gmail.com • WEBSITE https://millionpharma.com/eltrombopag- 75mg.php

More Related